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Abstract
Objective: We investigated the effectiveness of a self-help intervention named PER-
ANTARA, which aims to improve adherence to diagnostic procedures among women
with breast cancer (BC) symptoms to reduce the time to a definitive diagnosis.
Methods: With a cluster randomized crossover design across four hospitals, PER-
ANTARA and treatment as usual (TAU) or TAU only was provided at successive
periods in a randomly determined order. The main outcome was the time between
the first medical consultation and the definitive diagnosis. Secondary outcomes were
BC knowledge, measured by the Breast Cancer Knowledge Test (BCKT); symptoms
of anxiety and depression, measured by the Hospital Anxiety and Depression Scale
(HADS); quality of life, measured by the World Health Organization Quality of Life-
BREF (WHOQOL-BREF); and health status, measured by the EQ-5D-5L. A linear
mixed model analysis was conducted to analyse the outcomes.
Results:We recruited 132 women with BC symptoms from four hospitals; 67 partici-
pants were in the intervention group, and 65 participants were in the control group.
PERANTARA reduced the time to definitive diagnosis by 13.3 days (M [SD]: 25.90
[23.20] in the intervention group vs 39.29 [35.10] in the control group; mean differ-
ence = −13.26, 95% CI = −24.51 to −2.00, P = .02). No significant difference was
found between the groups in BC knowledge, symptoms of anxiety, depression, qual-
ity of life, or health status.
Conclusions: PERANTARA reduced the time to definitive diagnosis among Indone-
sian women with BC symptoms. Psychoeducation may be an important addition to
regular BC care to prevent undue delays in diagnostic procedures.
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1 | BACKGROUND
Breast cancer (BC) is a commonly diagnosed cancer and the leading
cause of cancer mortality among women in low- and middle-income
countries (LMICs), including Indonesia, where resources for preven-
tion, diagnosis, and treatment are limited.1 In the clinical BC manage-
ment, an accurate and timely diagnosis is critical.2
In Indonesia, over 80% of BC cases are found at an advanced
stage.3 When visiting the hospital to check for breast abnormalities,
approximately 67% of women do not pursue a definitive diagnosis.4
Women with BC who delayed hospital visits for treatment were
found to distrust medical procedures because of a perceived lack of
information regarding their positive effects.5 In contrast, many
patients prefer visiting alternative healers who are considered to be
more supportive, inexpensive, and effective.5,6 To improve access
and facilitate early diagnosis, interventions for women with early BC
symptoms should focus on addressing these barriers to reduce diag-
nosis delay.
A cross-sectional study among 70 women with BC in Indonesia
showed that 41% to 86% were not satisfied with information about
BC that they received.7 The provision of information about BC symp-
toms, diagnosis, and treatment through health education8 and support
in coping with psychosocial issues (psychoeducation) was useful for
promoting health behaviour changes and improving BC-related knowl-
edge, reducing anxiety and depression, and improving quality of life in
women with BC symptoms or BC survivors.9-12 However, no studies
have been conducted on the use of self-help interventions consisting
of health and psychoeducation to encourage women with BC symp-
toms to receive timely diagnoses.
We developed and evaluated a culturally sensitive, narrative self-
help intervention named PERANTARA (PEngantar peRAwataN
kesehaTAn payudaRA, translated as introduction to breast health
treatment,13 that aims to motivate women with BC symptoms to com-
ply with diagnostic procedures. PERANTARA consists of health edu-
cation and psychoeducation and uses a narrative strategy, which
involves the use of testimonials and storytelling.14 This strategy is
acceptable for patients with low health literacy for communication of
BC-related information.15-19
The primary aim of this study was to investigate the effectiveness
of PERANTARA in reducing the time (in days) from the first consulta-
tion with a doctor for BC symptoms to the time of a definitive diagno-
sis. The secondary aims were to examine the effects of PERANTARA
on BC knowledge, symptoms of anxiety and depression, quality of life,
and health status.
2 | METHODS
The study protocol has been published elsewhere.20 The study was
approved by the Health Research Ethics Committee of Dr. Hasan
Sadikin General Hospital in Bandung on 23 December 2013
(Document No: LB.04.01/A05/EC/127/XII/2013).
2.1 | Study design and participants
We used a cluster randomized crossover design in which four hospi-
tals in Bandung, West Java, Indonesia, provided either PERANTARA
plus treatment as usual (TAU) or TAU only to participants in a ran-
domly determined order (Appendix 1). Two predefined periods were
determined (Appendix 2). In the first period (January 2017-May
2017), two hospitals were allocated to the intervention group
(PERANTARA plus TAU), and two hospitals were allocated to the con-
trol group (TAU only). In the second period (February
2017-September 2017), the two hospitals allocated to the interven-
tion group were assigned to control, and vice versa. Randomization
was performed by a team member who was not involved in the data
collection.
The inclusion criteria were as follows: (a) newly admitted female
outpatients who visited the hospitals with BC symptoms before
obtaining a definitive diagnosis; (b) age 18 years and older;
(c) adequate command of the Indonesian language; and (d) no previ-
ous psychiatric consultations, as determined by medical records.
Power calculations suggested a minimum sample size of 41 partici-
pants per group (power = 0.80, alpha = 0.05 two-sided).20 To account
for 30% attrition at follow-up, we aimed to include at least 106 partici-
pants (53 per group).
2.2 | Procedures
Eligible patients were asked to provide oral and written informed con-
sent by research assistants with bachelor's degrees in psychology.
After the baseline assessment (T0), the participants in the intervention
group received PERANTARA and TAU, whereas those in the control
group received TAU. For the intervention group, the research assis-
tants provided a brief explanation and instruction about PERANTARA.
This group was then requested to view and read the PERANTARA
materials within 7 days following the baseline assessment. The post-
intervention assessment (T1) took place 7 days after the intervention,
and the follow-up assessment (T2) was scheduled for 3 months
(12 weeks) following T1.
2.3 | Intervention
PERANTARA is a self-help intervention that combines printed and
audio-visual health education and psychoeducation materials.13,20 The
printed material covers three core themes: (a) “What is in my breast?,”
providing a brief explanation of BC symptoms to promote an accurate
understanding of BC and consulting a doctor as a credible source;
(b) “Why should you immediately consult a doctor?,” offering a brief
explanation of breast examination procedures to raise awareness
about BC symptoms and increases motivation to follow diagnostic
procedures; and (c) “You are not alone,” recommending to seek sup-
port from significant persons and institutions. The audio-visual
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material consists of a DVD that provides the testimonials and stories
of two BC survivors who encourage patients to engage in active cop-
ing and seek social support and to follow medical procedures. A pilot
study showed that the prototype was feasible and acceptable.13 See
Appendix 3.
2.4 | Treatment as usual
TAU for women with BC symptoms in the four study hospitals con-
sists of consultations with an oncologist about medical examination
procedures and an educational poster on the wall in the hospital
waiting room. Psychosocial services are usually not provided.
2.5 | Measures
The background characteristics included age, marital status, education
level, income level, travel time to the hospital, insurance status, and
consultation with a traditional healer.
Time to diagnosis, defined as the time between the first consulta-
tion with a doctor for BC symptoms to the time (in days) of a defini-
tive diagnosis, was assessed using the following interview questions:
(a) What was the date that you consulted a doctor in the hospital
regarding your BC symptoms? (b) What was the date that you
received a definitive diagnosis? To identify whether the cause of the
delay was due to the patient or the doctor, we asked the following
questions: (a) On which date did your doctor schedule the examina-
tion (to make the definitive diagnosis)? (b) On which date did your
doctor schedule a consultation to provide the definitive diagnosis? To
verify the interview results, we compared the participants' responses
with both the individuals' and hospitals' medical records.
BC knowledge was assessed using the Indonesian version of the
Breast Cancer Knowledge Test (BCKT), a 20-item questionnaire that
consists of two subscales: (a) general knowledge (12 items) and
(b) curability (eight items).5,21 In this study, only the curability subscale
had acceptable reliability (Cronbach's coefficients of α = .54 at T0,
α = .52 at T1, and α = .69 at T2). Therefore, we decided to use only
the curability subscale (score range of 0-8, with higher scores indica-
tive of more knowledge about BC curability).
The 14-item, self-report Hospital Anxiety and Depression Scale
(HADS) measured symptoms of anxiety and depression during the
past week.22,23 The HADS consists of two subscales: anxiety (HADS-
A, 7 items, score range of 0-21) and depression (HADS-D, 7 items,
score range of 0-21). Higher scores indicate a higher symptom level.
The Indonesian version of the 26-itemWorld Health Organization
Quality of Life-BREF (WHOQOL-BREF)24-26 was used to measure
quality of life during the past 4 weeks. Two items measure quality of
life (score range of 0-100) and health satisfaction in general (score
range of 0-100). Twenty-four items measure four broad domains,
namely, physical health (seven items), psychological health (six items),
social relationships (three items), and environment (eight items).
Higher scores indicate better quality of life.
The Bahasa Indonesia version of the EQ-5D-5 L measured health
status. The EQ-5D-5L defines health in relation to five dimensions:
mobility (MO), self-care (SC), usual activities (UA), pain/discomfort
(PD), and anxiety/depression (AD), with five levels per dimension:
(a) no problems, (b) slight problems, (c) moderate problems, (d) severe
problems, and (e) extreme problems/unable. A single value indicates
the level selected for each dimension. The second part is a visual ana-
logue scale of overall health status (EQ-VAS), with scores ranging from
0 (“the worst health you can imagine”) to 100 (“the best health you
can imagine”). The EQ-5D-5L has been shown to be valid and reliable
when used in Indonesia.27,28
2.6 | Data analysis
We used chi-square tests and independent samples t tests in SPSS
version 24 to compare baseline demographic characteristics between
the intervention and control groups and between participants who
discontinued and who completed the study.
Outcome data were analysed using linear mixed models in R ver-
sion 1.1.423 with the Lme4 package.29,30 We followed the rec-
ommended procedures for multilevel modelling.31 An advantage of
mixed model analyses is that the full data set is used, including missing
data.32 A two-level model was used to analyse the primary outcome
(level 1: participant and level 2: hospital), and a three-level model (level
1: measurement time points [MTPs]; level 2: participant; and level 3:
hospital) was used to analyse the secondary outcomes. A generalized
mixed model was employed with treatment, MTPs, and the interaction
between PERANTARA and MTPs as fixed effects and hospital and sub-
ject as random effects. The difference in means between the two
groups (intervention and control group) at each MTP and the 95% CI
was derived from the generalized mixed model. The effect size was cal-
culated by subtracting the group means and dividing the result by the
standard deviation of the population from which the groups were sam-
pled. All analyses were described and agreed upon in the statistical
analysis plan before unmasking the study (Appendix 4).
3 | RESULTS
3.1 | Flow and characteristics of the participants
We approached 185 eligible participants, of whom 132 (71.4%) con-
sented to participate (67 in the intervention group and 65 in the control
group). For the primary outcome, we analysed the data of 107 partici-
pants, of whom 51 were in the intervention group and 56 were in the
control group. For the secondary outcomes, we assessed 67 participants
in the intervention group and 65 participants in the control group at
the baseline assessment (T0). At T1, the follow-up rates were 80.6%
(54/67) in the intervention group and 76.9% (50/65) in the control
group, and at T2, they were 52.2% (35/67) in the intervention group
and 61.5% (40/65) in the control group. The difference in attrition
between the primary and secondary outcomes was due to the primary
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outcome being based on both the interview and the hospital medical
records (n = 107), whereas the secondary outcomes were based on the
self-report instruments returned by 132 participants. No serious
adverse events were reported in either group.
There were no significant differences found in background charac-
teristics between the intervention and control groups (Table 1). In addi-
tion, background characteristics did not differ between the participants
who discontinued participation and those who completed the study.
3.2 | Outcomes
3.2.1 | Primary outcome (time to diagnosis)
The linear mixed model analysis (Table 2) showed a significantly larger
reduction in time (days) to diagnosis in the intervention group
(M = 25.90, SD = 23.20) than in the control group (M = 39.29, SD = 35.10).
PERANTARA reduced the time between the first visit to the hospital
TABLE 1 Baseline characteristics of the intervention and control groups and the results of the tests of differences (total n = 132)
Characteristics Intervention Group (n = 67) Control Group (n = 65) X or t df P value*
Age, mean (SD) 38.04 (11.89) 37.92 (14.65) −0.05 130 .96
Education, n (%) 2.66 2 .26
Basic 8 (11.90) 14 (21.60)
Middle 44 (65.70) 35 (53.80)
High 15 (22.40) 16 (24.60)
Hospital, n (%) 0.14 3 .99
Hospital A 20 (29.90) 21 (32.40)
Hospital B 9 (13.30) 9 (13.80)
Hospital C 20 (29.90) 19 (29.20)
Hospital D 18 (26.90) 16 (24.60)
Income, n (%)
<2 million Rupiah 28 (41.80) 32 (49.30) 2.24 2 .33
2-4 million Rupiah 27 (40.30) 27 (41.50)
>4 million Rupiah 12 (17.90) 6 (9.20)
Location/Residence 0.30 1 .58
Urban 31 (46.3) 27 (41.5)
Rural 36 (53.7) 38 (58.5)
Time to hospital, n (%) 0.09 1 .83
Less than an hour 55 (81.10) 52 (82.10)
Between 2 and 3 h 12 (18.90) 13 (17.90)
Alternative medicine n (%) 0.86 1 .41
No 54 (80.60) 48 (73.80)
Yes 13 (19.40) 17 (26.20)
Breast cancer knowledge test (BCKT)
Curability, mean (SD) 5.45 (1.74) 5.34 (1.76) −0.36 130 .72
Anxiety and Depression Symptoms (HADS)
Anxiety (HADS-A), mean (SD) 7.75 (3.43) 7.66 (4.37) −0.12 130 .90
Depression (HADS-D) 4.94 (3.02) 5.25 (3.35) 0.55 130 .58
Quality of Life (WHOQOL-BREF)
Physical health, mean (SD) 64.60 (14.49) 61.70 (13.28) −1.20 130 .23
Psychological, mean (SD) 63.30 (15.33) 61.73 (16.06) −0.58 130 .57
Social relationships, mean (SD) 63.05 (13.77) 62.56 (15.10) −0.20 130 .84
Environment, mean (SD) 60.16 (13.03) 58.36 (12.14) −0.82 130 .41
Health Status (EQ-5D-5L)
Index score, mean (SD) 0.77 (0.20) 0.74 (0.27) −0.81 130 .42
Visual analogue score, mean (SD) 71.30 (16.80) 66.91 (22.76) −1.27 130 .21
Note: Chi-square test for nominal variables and independent samples t tests for continuous variables.
*Significant at P < .05.
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and provision of a definitive diagnosis by an average of 13.3 (SE = 5.67;
95% CI = −24.51 to −2.00, P = .02) days. The effect size of the
between-group difference approached medium (Cohen's d = .43).
3.2.2 | Secondary outcomes
BC knowledge
The linear mixed models showed no significant difference in BCKT
curability between the intervention and control groups at T1 (M [SD]
5.81 [1.67] vs 5.64 [1.61], P = .88) or at T2 (M [SD] 5.69 [1.99] vs 5.08
[1.97], P = .09).
Symptoms of anxiety and depression
At T1, we found no significant difference between the intervention
and control groups in HADS anxiety (M [SD] 7.04 [3.77] vs 6.42
[4.16], P = .19) or HADS depression (4.69 [3.35] vs 5.16 [3.69],
P = .76) score. At T2, there was also no significant difference between
the intervention and control groups in HADS anxiety (M [SD] 5.23
[3.91] vs 5.73 [3.70], P = .55) or HADS depression (3.86 [3.21] vs 4.28
[3.11], P = .83) score.
Quality of life
The linear mixed model analysis on the WHOQOL-BREF scores
showed no significant difference between the intervention and control
groups at T1 in the physical health (M [SD] 62.63 [13.37] vs 62.50
[12.46], P = .41), psychological (62.34 [11.97] vs 63.00 [12.92], P = .49),
social relationships (61.72 [12.69] vs 63.33 [13.25], P = .3), or environ-
ment (59.31 [13.37] vs 56.68 [10.77], P = .4) domain score. At T2, there
was also no significant difference between the intervention and control
groups in the physical health (68.67 [11.19] vs 67.05 [12.80], P = .92),
psychological (66.19 [14.17] vs 66.25 [13.16], P = .41), social
TABLE 2 Statistics and test results for the primary and secondary outcomes
Outcomes
Measurement
Time
Descriptive Statistics
M (SD) Mixed Model Analysis
Intervention
Group
Control
Group
Difference in LS mean
(95% CI)
P
value*
Effect
sizea
Time to diagnosis 25.90 (23.20) 39.29 (35.10) −13.26 (−24.51 to −2.00) .02 0.43
Breast Cancer Knowledge Test (BCKT)
Curability T1 5.81 (1.67) 5.64 (1.61) 0.04 (−0.58 to 0.67) .88 ns
scale (0-8) T2 5.69 (1.99) 5.08 (1.97) 0.61 (−0.09 to 1.33) .09 ns
Anxiety and Depression Symptoms (HADS)
Anxiety (HADS-A) T1 7.04 (3.77) 6.42 (4.16) 0.83 (−0.42 to 2.10) .19 ns
scale (0-21) T2 5.23 (3.91) 5.73 (3.70) −0.43 (−1.89 to 1.01) .55 ns
Depression (HADS-
D)
T1 4.69 (3.35) 5.16 (3.69) −0.17 (−1.29 to 0.94) .76 ns
scale (0-21) T2 3.86 (3.21) 4.28 (3.11) 0.13 (−1.14 to 1.42) .83 ns
Quality of life (WHOQOL-BREF)
Physical health T1 62.63 (13.37) 62.50 (12.46) −1.87 (−6.37 to 2.62) .41 ns
scale (0-100) T2 68.67 (11.19) 67.05 (12.80) −0.27 (−5.47 to 4.92) .92 ns
Psychological T1 62.34 (11.97) 63.00 (12.92) −1.56 (−6.02 to 2.90) .49 ns
scale (0-100) T2 66.19 (14.17) 66.25 (13.16) −2.08 (−7.13 to 2.95) .41 ns
Social relationships T1 61.72 (12.69) 63.33 (13.25) −2.13 (−6.15 to 1.89) .3 ns
scale (0-100) T2 64.28 (14.93) 64.37 (14.24) −1.31 (−5.95 to 3.31) .57 ns
Environment T1 59.31 (13.37) 56.68 (10.77) 1.29 (−1.75 to 4.34) .4 ns
scale (0–100) T2 63.92 (12.73) 61.48 (12.92) 0.13 (−3.33 to 3.61) .94 ns
Health status (EQ-5D-5 L)
Index score T1 0.82 (0.15) 0.80 (0.20) 0.00 (−0.05 to 0.07) .77 ns
scale (0-1) T2 0.90 (0.21) 0.84 (0.17) 0.04 (−0.02 to 0.11) .22 ns
Visual analogue score T1 77.87 (13.76) 77.88 (16.58) −0.25 (−5.59 to 5.09) .93 ns
scale (0-100) T2 85.63 (11.10) 80.45 (14.42) 4.57 (−1.57 to 10.7) .14 ns
Note: The mixed model included treatment, time, and the interaction between treatment and visit as fixed effects, the baseline outcome measurement as
the covariate, and the hospital and subject as random effects.
*Significant at P < .05.
aThe effect size was calculated by dividing the LS mean by the SD.
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relationships (64.28 [14.93] vs 64.37 [14.24], P = .57), or environment
(63.92 [12.73] vs 61.48 [12.92], P = .94) domain score.
Health status
The linear mixed model analysis showed no significant difference
between the intervention and control groups at T1 in the EQ-5D-5L
index score (M [SD] 0.82 [0.15] vs 0.80 [0.20], P = .77) or the visual
analogue score (77.87 [13.76] vs 77.88 [16.58], P = .93). At T2, no sig-
nificant difference between the groups was found in the EQ-5D-5L
index score (0.90 [0.21] vs 0.84 [0.17], P = .22) or the visual analogue
score (85.63 [11.10] vs 80.45 [14.42], P = .14).
4 | DISCUSSION
The primary aim of the current study was to evaluate the effect of
PERANTARA on the time between the first consultation at the hospi-
tal regarding BC symptoms and the provision of a definitive diagnosis
among Indonesian women with early BC symptoms. The results of this
study confirm that PERANTARA had a small to medium effect
(Cohen's d = .43) in reducing the time to diagnosis by an average of
13.3 days, for an average of 27 days between the first consultation
and the definitive diagnosis. PERANTARA had no significant effect on
the secondary outcomes, that is, knowledge of BC curability, symp-
toms of anxiety and depression, quality of life, and health status.
Our study was the first evaluating a self-help intervention to
reduce the time between the first consult with a doctor and a defini-
tive diagnosis for women with BC symptoms in an under-resourced
LMIC setting such as Indonesia. Our findings are in line with previous
studies showing that self-help interventions promote health behav-
iour.10,12 However, we did not find reductions in anxiety and depres-
sion symptoms or improvements in quality of life or health status
comparing the intervention and control groups. This seems remark-
able since previous studies in Turkey and Taiwan found beneficial
effects of psychoeducation on anxiety, depression, and quality of
life.11,12 A plausible explanation is that PERANTARA lacks specific
guidance on how to adequately deal with distress to improve daily
functioning and quality of life.
4.1 | Study limitations
The limitations of the current study were that the four hospitals were
located in an urban setting and thus may have different characteris-
tics than rural hospitals in Indonesia. Another limitation was the eth-
nic homogeneity of the study sample, which may limit the
generalizability of our findings to other populations. Further, we
used only the time interval in days as our primary outcome. This
measure was chosen because of its feasibility and since the passage
of time is the crucial determining factor for tumour growth. How-
ever, we have only limited information concerning the reasons for
the delay and whether the delay was caused by the hospital or the
patient herself.
4.2 | Clinical implications
In conclusion, our findings provide evidence that PERANTARA can be
used to encourage women with BC symptoms to promptly consult an
oncologist and follow diagnostic procedures. This is important since
research has shown that Indonesian women with early BC symptoms
usually wait to visit a hospital until the disease is already in an advanced
stage33 or do not adhere to diagnostic procedures,4 which negatively
affects BC prognosis. The standards of the National Health Service of
England for waiting times for suspected and diagnosed cancer
patients34 suggest a maximum of 2 weeks before seeing a specialist for
further diagnostic follow-up for all patients with suspected BC symp-
toms referred by general practitioners. In our study, PERANTARA was
able to reduce the time to an average of 27 days. Since this period is still
almost 2 weeks longer than recommended, there is still room for
improvement. Nevertheless, our results underline that with relatively
low effort, it is possible to significantly improve adherence to diagnostic
procedures for BC. Further cultural adaptation of the PERANTARA pro-
gramme for other areas of Indonesia and for other LMIC settings is
recommended.
4.3 | Research implications
Future research could focus on the effectiveness of the different ele-
ments of the PERANTARA and on different delivery formats, such
internet, mobile phones, face-to-face (group or individual), or a
blended version of both self-help and health care intervention. Fur-
thermore, it is important to adapt PERANTARA to other BC
populations inside and outside of Indonesia, taking into account the
language, culture, and context to guarantee that it is compatible with
local cultural patterns, meanings and values.35
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[Correction added on 06 February 2020, after first online publication:
the order of references has been corrected throughout the article in
this current version.]
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